Press Releases September 18, 2026 08:00 AM

LifeVantage to Participate in the WTR Virtual Insights Conference on Wednesday, September 23, 2026

LifeVantage Announces CEO and CFO Participation in WTR Virtual Insights Conference

By Derek Hwang
Share
Twitter Reddit Facebook LinkedIn
LFVN

LifeVantage Corporation, a Nasdaq-listed health and wellness company, announces that its CEO Terrence Moorehead and CFO Carl Aure will participate in the WTR Virtual Insights Conference on September 23, 2026. The webcast aims to provide investors with insights into the company's products and business strategy.

LifeVantage to Participate in the WTR Virtual Insights Conference on Wednesday, September 23, 2026
LFVN
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • LifeVantage is a pioneer in nutrigenomics and offers a diverse range of scientifically validated health and nutrition products including Protandim®, TrueScience®, MindBody GLP-1 System®, and AXIO®.
  • The company’s executives will present at a virtual investor conference, providing transparency and engagement with the investment community.
  • LifeVantage operates with a direct sales model through independent consultants, targeting health-conscious consumers and entrepreneurs.

SALT LAKE CITY, Sept. 18, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that Terrence Moorehead, Chief Executive Officer, and Carl Aure, Chief Financial Officer, will participate in the upcoming WTR Virtual Insights Conference on Wednesday, September 23, 2026.

The webcast of the presentation will begin at approximately 1:30 p.m. Eastern Time on Wednesday, September 23, 2026. The event is open access for all investors and interested parties can register through the Company’s Investor Relations website at https://investor.lifevantage.com/events-and-presentations.

About LifeVantage Corporation

LifeVantage Corporation (Nasdaq: LFVN), the Activation company, is a pioneer in nutrigenomics—the study of how nutrition and naturally occurring compounds can unlock your genes and the health coded within. Our products work with your unique biology and help your body make what it needs for health. The line of scientifically validated activators includes the flagship Protandim® family of products, TrueScience® Liquid Collagen, the MindBody GLP-1 System®, the newest comprehensive gut activator from LoveBiome P84, the Activation-supporting nutrients such as Omega, D3+, and the Rise AM & Reset PM System®, as well as AXIO® nootropic and hydration energy drink mixes, the full TrueScience® line of skin and hair care products, and Petandim®, a pet supplement formulated to combat oxidative stress in dogs. Our independent Consultants sell our products to Customers and share the business opportunity with entrepreneurs seeking to begin their own business. LifeVantage was founded in 2003 and is headquartered in Lehi, Utah. For more information, visit www.lifevantage.com.

Investor Relations Contact:

Reed Anderson, ICR
(646) 277-1260
reed.anderson@icrinc.com


Risks

  • Market acceptance of LifeVantage’s products depends on scientific validation and consumer trust in nutrigenomics, which may vary.
  • The direct sales business model can be affected by competition and regulatory scrutiny impacting sales force recruitment and retention.
  • Uncertainty related to broader economic conditions may influence consumer discretionary spending on health and wellness products.

More from Press Releases

Alaunos Therapeutics, Inc. Announces Pricing of Registered Direct Offering priced at-the-market under Nasdaq rules Sep 18, 2026 Sagtec Global Completes Strategic Private Placement with His Royal Highness Prince Hassanal of Pahang, Malaysia Sep 18, 2026 Phaos Technology Holdings (Cayman) Limited Announces Update on Involvement of Related Parties Sep 18, 2026 Beeline Partners with Emmy Award-Winning Loft 100 Studios on ‘Bizumentary’ Exploring Mortgage Industry Challenges and Innovative Paths to Homeownership Sep 18, 2026 Silo Pharma Receives U.S. Patent Allowance for SPC-15 PTSD Treatment, Expanding Intellectual Property Portfolio Sep 18, 2026